Mercy BioAnalytics announced the close of a $59 million Series B round to support commercialization of its blood-based ovarian cancer tests designed for population screening and mass evaluation of women with pelvic masses. The technology detects tumor-specific proteins on extracellular vesicles (EVs), with ongoing efforts to expand assays to lung cancer and other malignancies. Mercy’s test portfolio recently received FDA breakthrough device designation, underscoring its potential to address critical gaps in early cancer diagnosis and improve patient outcomes. The financing drew participation from strategic investors including Novalis, American Cancer Society, and Laboratory Corporation of America.